Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Jnj-42165279. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH known ✓ | O00519 | 16/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj-42165279 SCHEMBL30201425 | 1.00 | FAAH (1.00) | FAAHCYP2D6CA12CA1CA2 | |
| Jnj-42165279 SCHEMBL29392521 | 1.00 | FAAH (1.00) | FAAHCYP2D6CA12CA1CA2 | |
| Jnj-42165279 SCHEMBL31616215 | 0.99 | FAAH (0.98) | FAAHCYP2D6CA12CA1CA2 | |
| Jnj-42165279 SCHEMBL2588988 | 0.99 | FAAH (0.98) | FAAHCYP2D6CA12CA1CA2 | |
| SCHEMBL15673544 | 0.86 | FAAH (0.76) | FAAHCYP2D6MCHR1 | |
| SCHEMBL3590970 | 0.84 | FAAH (1.00) | FAAHCYP2D6MAPK1 | |
| SCHEMBL2593197 | 0.83 | FAAH (1.00) | FAAHCYP2D6 | |
| SCHEMBL3637158 | 0.83 | FAAH (0.76) | FAAHCYP2D6MAPK1 | |
| SCHEMBL3598626 | 0.81 | FAAH (1.00) | FAAHCYP2D6MAPK1 | |
| SCHEMBL1277125 | 0.81 | FAAH (0.68) | FAAHCYP2D6MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115616216-A | Use of an agent that inhibits or blocks the interaction between FAAH and NLRP3 | 华南理工大学 | 2023-01-17 | — | — | CN | claimed |
| WO-2011139951-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-10 | — | — | WO | claimed |
| CN-115616216-A | Use of an agent that inhibits or blocks the interaction between FAAH and NLRP3 | 华南理工大学 | 2023-01-17 | — | — | CN | disclosed |
| EP-3823610-A1 | METHODS OF TREATING RENAL DISEASE | The Regents of the University of California (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020018554-A1 | METHODS OF TREATING RENAL DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-23 | — | — | WO | disclosed |
| US-9688664-B2 | Modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688664-B2 | Modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20150099761-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099761-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2015-04-09 | — | — | US | disclosed |
| US-8940745-B2 | Modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-27 | — | — | US | disclosed |
| US-8940745-B2 | Modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-27 | — | — | US | disclosed |
| EP-2566861-B1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-14 | — | — | EP | disclosed |
| US-20130053398-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053398-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011139951-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139951-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139951-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099761-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, APEH | FAAH 1/4885CYP2D6 1782/4885CA12 4559/4885 |
| US-20130053398-A1 | MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, APEH | FAAH 1/4885CYP2D6 1782/4885CA12 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.